1 |
IL31RA
| 1件: JAK-STAT signaling pathway JAK-STAT signaling pathway | D11080
D11080
|
Nemolizumab
| 1件: 51 51 |
2 |
CSF2
| 8件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Shigellosis, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Rheumatoid arthritis | D11343
D11343
|
Otilimab
| 1件: 46 46 |
3 |
CSF2RA
| 2件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Pathways in cancer | D05066
D05066
|
Molgramostim
| 3件: 97 97, 229, 299 |
4 |
CSF2RA
| 2件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Pathways in cancer | D05712
D05712
|
Regramostim
| 1件: 229 229 |
5 |
CSF2RA
| 2件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Pathways in cancer | D05803
D05803
|
Sargramostim
| 7件: 6 6, 28, 60, 62, 96, 229, 285 |
6 |
CSF2RA
| 2件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Pathways in cancer | D09930
D09930
|
Mavrilimumab
| 2件: 41 41, 46 |
7 |
CSF3R
| 3件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Pathways in cancer | D03235
D03235
|
Filgrastim
| 35件: 2 2, 6, 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 |
8 |
CSF3R
| 3件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Pathways in cancer | D03247
D03247
|
Lenograstim
| 7件: 2 2, 13, 16, 18, 19, 57, 65 |
9 |
CSF3R
| 3件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Pathways in cancer | D06889
D06889
|
Pegfilgrastim
| 1件: 60 60 |
10 |
EGFR
| 19件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D01977
D01977
|
Gefitinib
| 1件: 75 75 |
11 |
EGFR
| 19件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D03455
D03455
|
Cetuximab
| 2件: 51 51, 86 |
12 |
EGFR
| 19件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D07907
D07907
|
Erlotinib
| 1件: 94 94 |
13 |
EGFR
| 19件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08108
D08108
|
Lapatinib
| 3件: 34 34, 74, 75 |
14 |
EGFR
| 19件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08950
D08950
|
Neratinib
| 1件: 34 34 |
15 |
EGFR
| 19件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11251
D11251
|
Icotinib
| 1件: 34 34 |
16 |
EGFR
| 19件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11772
D11772
|
Tesevatinib
| 1件: 67 67 |
17 |
EPOR
| 3件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Pathways in cancer | D09946
D09946
|
Peginesatide
| 1件: 283 283 |
18 |
MTOR
| 21件: Phospholipase D signaling pathway Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00753
D00753
|
Sirolimus
| 40件: 2 2, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 |
19 |
MTOR
| 21件: Phospholipase D signaling pathway Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D02714
D02714
|
Everolimus
| 9件: 34 34, 67, 89, 96, 137, 157, 158, 228, 277 |
20 |
MTOR
| 21件: Phospholipase D signaling pathway Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D06068
D06068
|
Temsirolimus
| 1件: 13 13 |
21 |
GHR
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway | D03297
D03297
|
Mecasermin
| 6件: 65 65, 78, 96, 168, 265, 299 |
22 |
GHR
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway | D05394
D05394
|
Pegvisomant
| 2件: 78 78, 265 |
23 |
GHR
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway | D11193
D11193
|
Somavaratan
| 1件: 78 78 |
24 |
GHR
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway | D11194
D11194
|
Somapacitan
| 2件: 78 78, 195 |
25 |
GHR
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway | D11486
D11486
|
Lonapegsomatropin
| 1件: 78 78 |
26 |
IFNA1
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
27 |
IFNA1
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
28 |
IFNA2
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
29 |
IFNA2
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
30 |
IFNA4
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
31 |
IFNA4
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
32 |
IFNA5
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
33 |
IFNA5
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
34 |
IFNA6
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
35 |
IFNA6
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
36 |
IFNA7
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
37 |
IFNA7
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
38 |
IFNA8
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
39 |
IFNA8
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
40 |
IFNA10
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
41 |
IFNA10
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
42 |
IFNA13
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
43 |
IFNA13
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
44 |
IFNA14
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
45 |
IFNA14
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
46 |
IFNA16
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
47 |
IFNA16
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
48 |
IFNA17
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
49 |
IFNA17
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
50 |
IFNA21
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
51 |
IFNA21
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
52 |
IFNAR1
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer | D00745
D00745
|
Interferon alfa-2a
| 1件: 56 56 |
53 |
IFNAR1
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer | D00746
D00746
|
Interferon beta-1b
| 1件: 13 13 |
54 |
IFNAR1
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer | D02745
D02745
|
Interferon alfa-2b
| 2件: 25 25, 34 |
55 |
IFNAR1
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer | D03305
D03305
|
Interferon alfa
| 6件: 13 13, 25, 26, 28, 56, 96 |
56 |
IFNAR1
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer | D04554
D04554
|
Interferon beta-1a
| 4件: 13 13, 26, 96, 97 |
57 |
IFNAR1
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer | D10483
D10483
|
Peginterferon beta-1a
| 1件: 13 13 |
58 |
IFNAR1
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer | D11082
D11082
|
Anifrolumab
| 3件: 46 46, 49, 53 |
59 |
IFNAR2
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer | D00745
D00745
|
Interferon alfa-2a
| 1件: 56 56 |
60 |
IFNAR2
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer | D00746
D00746
|
Interferon beta-1b
| 1件: 13 13 |
61 |
IFNAR2
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer | D02745
D02745
|
Interferon alfa-2b
| 2件: 25 25, 34 |
62 |
IFNAR2
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer | D03305
D03305
|
Interferon alfa
| 6件: 13 13, 25, 26, 28, 56, 96 |
63 |
IFNAR2
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer | D04554
D04554
|
Interferon beta-1a
| 4件: 13 13, 26, 96, 97 |
64 |
IFNAR2
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer | D10483
D10483
|
Peginterferon beta-1a
| 1件: 13 13 |
65 |
IFNAR2
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer | D11082
D11082
|
Anifrolumab
| 3件: 46 46, 49, 53 |
66 |
IFNG
| 18件: Proteasome Proteasome, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D04242
D04242
|
Fontolizumab
| 1件: 46 46 |
67 |
IFNG
| 18件: Proteasome Proteasome, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D11120
D11120
|
Emapalumab
| 3件: 49 49, 65, 107 |
68 |
IFNGR1
| 12件: Necroptosis Necroptosis, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00747
D00747
|
Interferon gamma-1b
| 7件: 18 18, 65, 85, 228, 299, 301, 326 |
69 |
IFNGR2
| 11件: Necroptosis Necroptosis, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00747
D00747
|
Interferon gamma-1b
| 7件: 18 18, 65, 85, 228, 299, 301, 326 |
70 |
IL2RA
| 7件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer | D00748
D00748
|
Aldesleukin
| 6件: 2 2, 35, 49, 65, 96, 97 |
71 |
IL2RA
| 7件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer | D03058
D03058
|
Basiliximab
| 6件: 2 2, 50, 66, 97, 222, 228 |
72 |
IL2RA
| 7件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer | D03639
D03639
|
Daclizumab
| 8件: 13 13, 56, 60, 65, 97, 107, 283, 284 |
73 |
IL2RB
| 8件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Transcriptional misregulation in cancer | D00748
D00748
|
Aldesleukin
| 6件: 2 2, 35, 49, 65, 96, 97 |
74 |
IL2RG
| 8件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Primary immunodeficiency | D00748
D00748
|
Aldesleukin
| 6件: 2 2, 35, 49, 65, 96, 97 |
75 |
IL4
| 7件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Leishmaniasis, Pathways in cancer | D03117
D03117
|
Binetrakin
| 1件: 46 46 |
76 |
IL4R
| 5件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Pathways in cancer | D10354
D10354
|
Dupilumab
| 5件: 51 51, 97, 98, 160, 162 |
77 |
IL5
| 4件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Pathways in cancer | D04923
D04923
|
Mepolizumab
| 4件: 44 44, 45, 98, 162 |
78 |
IL5
| 4件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Pathways in cancer | D08985
D08985
|
Reslizumab
| 2件: 44 44, 98 |
79 |
IL5RA
| 2件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Pathways in cancer | D09874
D09874
|
Benralizumab
| 5件: 44 44, 45, 98, 162, 299 |
80 |
IL6
| 23件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis, Lipid and atherosclerosis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
81 |
IL6
| 23件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis, Lipid and atherosclerosis | D08976
D08976
|
Pomalidomide
| 5件: 28 28, 51, 85, 227, 331 |
82 |
IL6
| 23件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis, Lipid and atherosclerosis | D09669
D09669
|
Siltuximab
| 2件: 28 28, 331 |
83 |
IL6
| 23件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis, Lipid and atherosclerosis | D10080
D10080
|
Sirukumab
| 2件: 41 41, 46 |
84 |
IL6
| 23件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis, Lipid and atherosclerosis | D12487
D12487
|
Olokizumab
| 2件: 46 46, 96 |
85 |
IL6R
| 6件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Non-alcoholic fatty liver disease, Pathways in cancer | D02596
D02596
|
Tocilizumab
| 21件: 2 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 |
86 |
IL6R
| 6件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Non-alcoholic fatty liver disease, Pathways in cancer | D10161
D10161
|
Sarilumab
| 5件: 41 41, 46, 84, 107, 271 |
87 |
IL6R
| 6件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Non-alcoholic fatty liver disease, Pathways in cancer | D11079
D11079
|
Satralizumab
| 3件: 11 11, 13, 86 |
88 |
IL10
| 11件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, JAK-STAT signaling pathway, T cell receptor signaling pathway, Pertussis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Systemic lupus erythematosus | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
89 |
IL11RA
| 1件: JAK-STAT signaling pathway JAK-STAT signaling pathway | D05266
D05266
|
Oprelvekin
| 2件: 96 96, 288 |
90 |
IL12A
| 14件: Toll-like receptor signaling pathway Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09214
D09214
|
Ustekinumab
| 16件: 37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
91 |
IL12B
| 14件: Toll-like receptor signaling pathway Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Proteoglycans in cancer, Lipid and atherosclerosis | D09214
D09214
|
Ustekinumab
| 16件: 37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
92 |
IL13
| 3件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Pathways in cancer | D08857
D08857
|
Anrukinzumab
| 1件: 97 97 |
93 |
IL13
| 3件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Pathways in cancer | D09633
D09633
|
Lebrikizumab
| 1件: 85 85 |
94 |
IL13
| 3件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Pathways in cancer | D09979
D09979
|
Tralokinumab
| 2件: 85 85, 97 |
95 |
JAK1
| 17件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09959
D09959
|
Ruxolitinib
| 3件: 60 60, 65, 228 |
96 |
JAK1
| 17件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09970
D09970
|
Tofacitinib
| 15件: 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 |
97 |
JAK1
| 17件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10308
D10308
|
Baricitinib
| 13件: 2 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 |
98 |
JAK1
| 17件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10653
D10653
|
Peficitinib
| 1件: 46 46 |
99 |
JAK1
| 17件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10871
D10871
|
Filgotinib
| 6件: 46 46, 53, 96, 97, 222, 271 |
100 |
JAK1
| 17件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10944
D10944
|
Itacitinib
| 4件: 46 46, 51, 97, 228 |
101 |
JAK1
| 17件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10994
D10994
|
Upadacitinib
| 8件: 40 40, 41, 46, 49, 96, 97, 107, 271 |
102 |
JAK1
| 17件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11400
D11400
|
Abrocitinib
| 1件: 84 84 |
103 |
JAK2
| 14件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09959
D09959
|
Ruxolitinib
| 3件: 60 60, 65, 228 |
104 |
JAK2
| 14件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09970
D09970
|
Tofacitinib
| 15件: 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 |
105 |
JAK2
| 14件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D10308
D10308
|
Baricitinib
| 13件: 2 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 |
106 |
JAK2
| 14件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D10653
D10653
|
Peficitinib
| 1件: 46 46 |
107 |
JAK3
| 11件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency | D09970
D09970
|
Tofacitinib
| 15件: 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 |
108 |
JAK3
| 11件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency | D10653
D10653
|
Peficitinib
| 1件: 46 46 |
109 |
LEPR
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease | D05014
D05014
|
Metreleptin
| 1件: 265 265 |
110 |
MPL
| 1件: JAK-STAT signaling pathway JAK-STAT signaling pathway | D08990
D08990
|
Romiplostim
| 4件: 60 60, 63, 64, 65 |
111 |
MPL
| 1件: JAK-STAT signaling pathway JAK-STAT signaling pathway | D10306
D10306
|
Avatrombopag
| 2件: 60 60, 63 |
112 |
IL20
| 2件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, JAK-STAT signaling pathway | D11756
D11756
|
Fletikumab
| 1件: 46 46 |
113 |
IL22
| 2件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Th17 cell differentiation | D11953
D11953
|
Efmarodocokin alfa
| 2件: 96 96, 97 |
114 |
IL23A
| 6件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Rheumatoid arthritis | D09214
D09214
|
Ustekinumab
| 16件: 37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
115 |
IL23A
| 6件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Rheumatoid arthritis | D10400
D10400
|
Tildrakizumab
| 2件: 162 162, 271 |
116 |
IL23A
| 6件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Rheumatoid arthritis | D10438
D10438
|
Guselkumab
| 5件: 37 37, 41, 51, 96, 97 |
117 |
IL23A
| 6件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Rheumatoid arthritis | D10912
D10912
|
Brazikumab
| 2件: 96 96, 97 |
118 |
IL23A
| 6件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Rheumatoid arthritis | D11052
D11052
|
Risankizumab
| 4件: 37 37, 96, 97, 271 |
119 |
IL23A
| 6件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Rheumatoid arthritis | D11123
D11123
|
Mirikizumab
| 3件: 37 37, 96, 97 |
120 |
PDGFRA
| 11件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma | D08066
D08066
|
Imatinib
| 12件: 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
121 |
PDGFRA
| 11件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma | D08552
D08552
|
Sunitinib
| 2件: 28 28, 34 |
122 |
PDGFRA
| 11件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma | D08953
D08953
|
Nilotinib
| 5件: 6 6, 8, 34, 51, 86 |
123 |
PDGFRA
| 11件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma | D10481
D10481
|
Nintedanib
| 5件: 51 51, 85, 89, 227, 228 |
124 |
PDGFRB
| 11件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma | D03658
D03658
|
Dasatinib
| 2件: 51 51, 85 |
125 |
PDGFRB
| 11件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma | D06414
D06414
|
Dasatinib
| 2件: 51 51, 85 |
126 |
PDGFRB
| 11件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma | D08524
D08524
|
Sorafenib
| 2件: 34 34, 86 |
127 |
PDGFRB
| 11件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma | D08552
D08552
|
Sunitinib
| 2件: 28 28, 34 |
128 |
PDGFRB
| 11件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma | D08953
D08953
|
Nilotinib
| 5件: 6 6, 8, 34, 51, 86 |
129 |
PDGFRB
| 11件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma | D10481
D10481
|
Nintedanib
| 5件: 51 51, 85, 89, 227, 228 |
130 |
PIK3CA
| 50件: Metabolic pathways Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D11011
D11011
|
Alpelisib
| 1件: 138 138 |
131 |
PIK3CA
| 50件: Metabolic pathways Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D11158
D11158
|
Leniolisib
| 2件: 53 53, 65 |
132 |
PIK3CB
| 50件: Metabolic pathways Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D11158
D11158
|
Leniolisib
| 2件: 53 53, 65 |
133 |
PIK3CD
| 50件: Metabolic pathways Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D11158
D11158
|
Leniolisib
| 2件: 53 53, 65 |
134 |
PIK3CD
| 50件: Metabolic pathways Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D11437
D11437
|
Parsaclisib
| 3件: 35 35, 53, 61 |
135 |
PRL
| 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway | D00987
D00987
|
Cabergoline
| 3件: 6 6, 74, 75 |
136 |
PRL
| 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway | D01348
D01348
|
Terguride
| 2件: 51 51, 86 |
137 |
PRL
| 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway | D03165
D03165
|
Bromocriptine
| 2件: 6 6, 74 |
138 |
RAF1
| 39件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08524
D08524
|
Sorafenib
| 2件: 34 34, 86 |
139 |
BCL2
| 22件: Platinum drug resistance Platinum drug resistance, NF-kappa B signaling pathway, Sphingolipid signaling pathway, p53 signaling pathway, Protein processing in endoplasmic reticulum, PI3K-Akt signaling pathway, Necroptosis, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Neurotrophin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Shigellosis, Salmonella infection, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Small cell lung cancer, Lipid and atherosclerosis | D10679
D10679
|
Venetoclax
| 1件: 28 28 |
140 |
TYK2
| 9件: Necroptosis Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Measles, Kaposi sarcoma-associated herpesvirus infection | D09970
D09970
|
Tofacitinib
| 15件: 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 |
141 |
TYK2
| 9件: Necroptosis Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Measles, Kaposi sarcoma-associated herpesvirus infection | D11817
D11817
|
Deucravacitinib
| 3件: 49 49, 96, 97 |
142 |
TSLP
| 1件: JAK-STAT signaling pathway JAK-STAT signaling pathway | D11771
D11771
|
Tezepelumab
| 1件: 98 98 |